MX338426B - Enzima de enfermedad del almacenamiento lisosomico. - Google Patents

Enzima de enfermedad del almacenamiento lisosomico.

Info

Publication number
MX338426B
MX338426B MX2012012356A MX2012012356A MX338426B MX 338426 B MX338426 B MX 338426B MX 2012012356 A MX2012012356 A MX 2012012356A MX 2012012356 A MX2012012356 A MX 2012012356A MX 338426 B MX338426 B MX 338426B
Authority
MX
Mexico
Prior art keywords
acid lipase
lysosomal acid
lysosomal storage
storage disease
human lysosomal
Prior art date
Application number
MX2012012356A
Other languages
English (en)
Other versions
MX2012012356A (es
Inventor
Anthony Quinn
Alex J Harvey
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of MX2012012356A publication Critical patent/MX2012012356A/es
Publication of MX338426B publication Critical patent/MX338426B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01013—Sterol esterase (3.1.1.13)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/30—Bird
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)

Abstract

La presente invención se refiere a una formulación farmacéutica que comprende una lipasa ácida lisosomal recombinante humana aislada (rhLAL) en combinación con un portador, diluyente o excipiente farmacéuticamente estable, en donde dicho rhLAL comprende una o más estructura N-glicanos, en donde el rhLAL se encuentra glicosilada unida por N en Asn15, Asn80, Asn140, Asn252 y Asn300 de la SEQ ID NO: 2, y en donde la formulación farmacéutica es una solución acuosa que tiene un pH de entre 5.6 y 6.2 o un pH de 5.9+-0.2.
MX2012012356A 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico. MX338426B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34317710P 2010-04-23 2010-04-23
US39637610P 2010-05-26 2010-05-26
US40301110P 2010-09-09 2010-09-09
US45601410P 2010-10-29 2010-10-29
US201161432372P 2011-01-13 2011-01-13
PCT/US2011/033699 WO2011133960A2 (en) 2010-04-23 2011-04-23 Lysosomal storage disease enzyme

Publications (2)

Publication Number Publication Date
MX2012012356A MX2012012356A (es) 2013-04-11
MX338426B true MX338426B (es) 2016-04-15

Family

ID=44834852

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004772A MX362430B (es) 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico.
MX2012012356A MX338426B (es) 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016004772A MX362430B (es) 2010-04-23 2011-04-23 Enzima de enfermedad del almacenamiento lisosomico.

Country Status (21)

Country Link
US (4) US20130209436A1 (es)
EP (3) EP3205351B1 (es)
JP (4) JP5925187B2 (es)
KR (1) KR101742346B1 (es)
CN (2) CN102985538B (es)
AU (1) AU2011242461B2 (es)
BR (1) BR112012027143B1 (es)
CA (2) CA2995446C (es)
DK (2) DK3205351T3 (es)
ES (2) ES2950358T3 (es)
FI (1) FI3205351T3 (es)
HK (1) HK1219655A1 (es)
HU (2) HUE033217T2 (es)
IL (2) IL222513A0 (es)
LT (1) LT3205351T (es)
MX (2) MX362430B (es)
PL (2) PL2561069T3 (es)
PT (2) PT3205351T (es)
RU (2) RU2015151189A (es)
SI (2) SI3205351T1 (es)
WO (1) WO2011133960A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849257B2 (en) 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
WO2008091311A1 (en) * 2007-01-26 2008-07-31 Synageva Biopharma Corp Transgene expression in avians
FI3205351T3 (fi) 2010-04-23 2023-07-06 Alexion Pharma Inc Lysosomaalisen kertymätaudin entsyymi
KR20150038636A (ko) 2010-09-09 2015-04-08 시나게바 바이오파르마, 코포레이션 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
WO2013131014A1 (en) * 2012-03-02 2013-09-06 Synageva Biopharma Corp. Truncated lysosomal acid lipase
AU2015249902B2 (en) * 2014-04-23 2019-01-31 Alexion Pharmaceuticals, Inc. Egg white processing
US11235036B2 (en) 2016-06-17 2022-02-01 Alexion Pharmaceuticals, Inc. Lysosomal acid lipase deficiency compositions and methods
JP7027347B2 (ja) * 2016-08-23 2022-03-01 アレクシオン ファーマシューティカルズ インコーポレイテッド 卵白から異種タンパク質を精製する方法
US20200038491A1 (en) 2016-09-30 2020-02-06 Alexion Pharmaceuticals, Inc. Methods for reducing liver fibrosis and treating lysosomal acid lipase deficiency in patients based on ishak fibrosis stage
US10633705B2 (en) 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
WO2019152343A1 (en) * 2018-02-01 2019-08-08 Alexion Pharmaceuticals, Inc. Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (lal-d) patients treated with exogenous lysosomal acid lipase (lal
US12492412B2 (en) * 2019-07-02 2025-12-09 M6P Terapeutics (Switzerland) Llc Vector compositions and methods of using same for treatment of lysosomal storage disorders
CN114369620B (zh) * 2021-12-31 2024-05-24 广州博垚生物科技有限公司 一种可持续分泌lal的载体、脐带间充质干细胞及其构建方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001985D0 (sv) * 1990-06-01 1990-06-01 Astra Ab New chemical products
AU1580292A (en) 1991-03-13 1992-10-21 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU3275595A (en) 1994-08-05 1996-03-04 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
ES2326705T3 (es) 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
MX340738B (es) 1996-09-13 2016-07-22 Shire Human Genetic Therapies Terapia para deficiencia de a-galactosidasa a.
US5897998A (en) 1997-08-04 1999-04-27 The University Of Georgia Research Foundation, Inc. Method for manipulating avian eggs
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US20030166132A1 (en) 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2312222T3 (es) 1998-12-07 2009-02-16 Genzyme Corporation Tratamiento de la enfermedad de pompe.
US7033780B1 (en) 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6849257B2 (en) * 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO2002036754A2 (en) 2000-10-31 2002-05-10 Bayer Aktiengesellschaft Nucleotide and polypeptide sequence of human lysosomal acid lipase
US20030064437A1 (en) 2000-11-15 2003-04-03 Nick Wan Expression system for recombinant proteins
US20020193303A1 (en) 2001-01-25 2002-12-19 Millennium Pharmaceuticals, Inc. 58860, a human cholesteryl ester hydrolase and uses therefor
US6387680B1 (en) * 2001-03-29 2002-05-14 Pe Corporation (Ny) Isolated human lipase proteins, nucleic acid molecules encoding human lipase proteins, and uses thereof
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2003064614A2 (en) 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
ES2498369T3 (es) 2002-04-16 2014-09-24 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Un marcador para medir cirrosis hepática
CA2499188A1 (en) 2002-09-27 2004-04-08 Cold Spring Harbor Laboratory Cell-based rna interference and related methods and compositions
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20070270364A1 (en) 2004-06-15 2007-11-22 Mayo Foundation For Medical Education And Research Helicases
CA2577690C (en) 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
US20070270367A1 (en) 2005-05-18 2007-11-22 University Of Kentucky Research Foundation Rybozyme-catalyzed insertion of targeted sequences into RNA
US8124732B2 (en) * 2005-06-24 2012-02-28 Synageva Biopharma Corp. Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
CA2622074C (en) 2005-10-05 2013-01-22 Avigenics, Inc. Rapid production of high titer virus
AU2006304856A1 (en) 2005-10-21 2007-04-26 Synageva Biopharma Corp. Glycolated and glycosylated poultry derived therapeutic proteins
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
US20080025959A1 (en) 2006-05-24 2008-01-31 Richard Daneman Permeability of blood-brain barrier
WO2008091311A1 (en) 2007-01-26 2008-07-31 Synageva Biopharma Corp Transgene expression in avians
US8143265B2 (en) 2007-04-16 2012-03-27 Meharry Medical College Method of treating atherosclerosis
US8466118B2 (en) 2007-04-23 2013-06-18 Saint Louis University Modulation of blood brain barrier protein expression
EP3486653A1 (en) 2007-05-24 2019-05-22 The United States Government as represented by The Department of Veterans Affairs Treatment of skeletal muscle disorder using ent2
NZ601148A (en) 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of allergic rhinitis
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
WO2009032171A1 (en) 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
CN101932231A (zh) * 2008-01-07 2010-12-29 辛那杰瓦生物制药股份有限公司 禽类的糖基化
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
WO2010078515A2 (en) 2009-01-02 2010-07-08 Zacharon Pharmaceuticals, Inc. Polymer end group detection
US8257694B2 (en) 2009-05-14 2012-09-04 Product Partners, Llc Nutritional compositions for reducing oxidative damage
US8962573B2 (en) 2009-07-03 2015-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
SI2995306T1 (sl) 2009-10-19 2019-04-30 Amicus Therapeutics, Inc. Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja
KR101077618B1 (ko) 2009-11-13 2011-10-27 경북대학교 산학협력단 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US20150030582A1 (en) * 2010-04-23 2015-01-29 Synageva Biopharma Corp. Lysosomal Storage Disease Enzyme
FI3205351T3 (fi) * 2010-04-23 2023-07-06 Alexion Pharma Inc Lysosomaalisen kertymätaudin entsyymi
KR20150038636A (ko) 2010-09-09 2015-04-08 시나게바 바이오파르마, 코포레이션 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
WO2012112677A2 (en) 2011-02-15 2012-08-23 Children's Hospital Medical Center Methods for treating lysosomal acid lipase deficiency
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
EP2709670A4 (en) 2011-05-18 2015-01-21 Childrens Hosp Medical Center TARGETED TRANSFER OF PROTEINS OVER THE BLOOD BRAIN BARRIER
US9155784B2 (en) 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2012177639A2 (en) 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
EP2753704A4 (en) 2011-08-03 2015-07-08 Lotus Tissue Repair Inc COLLAGEN 7 AND ASSOCIATED METHODS

Also Published As

Publication number Publication date
RU2017105260A (ru) 2018-08-17
US20170314000A1 (en) 2017-11-02
EP4241854A2 (en) 2023-09-13
PT2561069T (pt) 2017-05-22
JP2018100289A (ja) 2018-06-28
JP5925187B2 (ja) 2016-05-25
MX2012012356A (es) 2013-04-11
LT3205351T (lt) 2023-07-25
SI2561069T1 (sl) 2017-07-31
DK3205351T3 (da) 2023-06-19
AU2011242461A1 (en) 2012-11-15
BR112012027143B1 (pt) 2020-02-11
US10858638B2 (en) 2020-12-08
HUE033217T2 (hu) 2017-11-28
CN102985538A (zh) 2013-03-20
JP6496690B2 (ja) 2019-04-03
DK2561069T3 (en) 2017-05-01
CA2796607C (en) 2019-09-10
JP2016190867A (ja) 2016-11-10
PT3205351T (pt) 2023-06-28
RU2012149936A (ru) 2014-05-27
KR20130113312A (ko) 2013-10-15
US20200063113A1 (en) 2020-02-27
ES2950358T3 (es) 2023-10-09
AU2011242461B2 (en) 2015-10-01
ES2627535T3 (es) 2017-07-28
EP2561069A4 (en) 2014-03-26
PL2561069T3 (pl) 2017-08-31
CN105214076A (zh) 2016-01-06
JP2013526856A (ja) 2013-06-27
EP2561069B1 (en) 2017-03-08
IL252115B (en) 2019-11-28
JP6212081B2 (ja) 2017-10-11
MX362430B (es) 2019-01-17
RU2741116C2 (ru) 2021-01-22
CN102985538B (zh) 2015-09-09
WO2011133960A9 (en) 2013-06-13
SI3205351T1 (sl) 2023-09-29
CA2995446A1 (en) 2011-10-27
BR112012027143A2 (pt) 2016-11-16
EP4241854A3 (en) 2023-11-08
RU2017105260A3 (es) 2020-06-15
RU2015151189A (ru) 2019-01-14
IL252115A0 (en) 2017-07-31
CN105214076B (zh) 2020-03-31
WO2011133960A2 (en) 2011-10-27
BR112012027143A8 (pt) 2017-09-19
EP3205351A1 (en) 2017-08-16
IL222513A0 (en) 2012-12-31
WO2011133960A3 (en) 2012-07-12
HUE062163T2 (hu) 2023-09-28
KR101742346B1 (ko) 2017-06-15
HK1219655A1 (zh) 2017-04-13
FI3205351T3 (fi) 2023-07-06
CA2995446C (en) 2020-05-12
EP2561069A2 (en) 2013-02-27
US20210171922A1 (en) 2021-06-10
CA2796607A1 (en) 2011-10-27
US11560554B2 (en) 2023-01-24
HK1183059A1 (en) 2013-12-13
EP3205351B1 (en) 2023-04-12
PL3205351T3 (pl) 2023-08-28
US20130209436A1 (en) 2013-08-15
US10407671B2 (en) 2019-09-10
JP2015204842A (ja) 2015-11-19

Similar Documents

Publication Publication Date Title
MX362430B (es) Enzima de enfermedad del almacenamiento lisosomico.
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EA201291024A1 (ru) Композиции эндорибонуклеаз и способы их использования
UA109418C2 (uk) Конструйований білок з цинковими пальцями, направлений на гени рослин, залучені до біосинтезу жирних кислот
MX343049B (es) Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
MX2017011004A (es) Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.
MX352023B (es) Variantes de alfa-amilasa con estabilidad mejorada.
EP2493507A4 (en) AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
MX2017001898A (es) Peptidos que contienen manosa-6-fosfato fusionados a enzimas lisosomales.
WO2010148253A3 (en) Formulations for lysosomal enzymes
EP4253534A3 (en) Alpha-amylase variants and polynucleotides encoding same
WO2010135836A8 (en) Novel beta-glucosidase enzymes
NZ701125A (en) Improved chymosine enzyme variants
WO2011113027A3 (en) Npp1 fusion proteins
WO2012064709A3 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
MX2013003237A (es) Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos.
MX2013003236A (es) Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos.
WO2012064146A3 (ko) Ｇｋｎ １을 함유하는 항암용 조성물
WO2010120541A3 (en) Compositions and methods for modulating the activity of complement regulatory proteins on target cells
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
WO2011142832A3 (en) Stem cells derived under low oxygen conditions
EP2557938A4 (en) PROTECTED ALPHA AMYLASE

Legal Events

Date Code Title Description
FG Grant or registration